GMAB News and Press, Genmab A/S From 11/11/22

Deutsche Bank downgraded Genmab ( GMAB ) to hold from buy saying that it is does not expect upcoming data on candidates to be presented at two upcoming conferences to lead to upside. The firm has a price target of DKK 3100 (~3% upside based on Friday's close on the Copenhagen ...

Genmab A/S (GMAB) Q3 2022 Earnings Conference Call November 9, 2022 12:00 PM ET Company Participants Jan van de Winkel – Chief Executive Officer Anthony Pagano – Chief Financial Officer Tahi Ahmadi – Chief Medical Officer Conference Cal...

Genmab A/S press release ( GMAB ): Q3 GAAP EPS of DKK39.17. Revenue of DKK4.09B (+77.1% Y/Y). The company expects FY2022 net sales in the range of DKK13.5B to DKK14.5B from prior outlook of DKK12B to DKK13B. Operating profit to come in the range of DKK5.1B to DKK6.5B. ...

Genmab A/S ( GMAB ) is scheduled to announce Q3 earnings results on Wednesday, November 9th, before market open. The consensus EPS Estimate is $0.22 and the consensus Revenue Estimate is $486.47M (-78.9% Y/Y). Over the last 3 months, EPS estimates have seen 1 upward revi...

Summary As a company, Genmab has brought valuable medicines for patients. However, as a stock, it seems to be lagging, waiting for that blockbuster potential to be tapped. I will wait for a better price. I first covered Genmab A/S ( GMAB ) in December 2020, a...

Genmab ( GMAB ) on Thursday raised its 2022 revenue guidance on the back of a positive foreign exchange rate impact on its royalty revenue and strong net sales of cancer drug Darzalex. The Danish biotech now expects 2022 revenue to be in the range of DKK 13.5B to DKK ...

Nineteen abstracts accepted, including multiple presentations on the safety and efficacy of investigational epcoritamab (DuoBody ® -CD3xCD20) in a variety of treatment settings and hematologic malignancies Four oral presentations highlighting data evaluating epcorit...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips While the market volatility of 2022 opened doors for intriguing discounts, investors may want to consider allocating some of their funds toward undervalued biotech stocks. Fundamentally, the underlying industry represents t...

Genmab has Submitted Biologics License Application (BLA) to U.S. Food and Drug Administration (FDA) for epcoritamab European Medicines Agency (EMA) has validated Marketing Authorization Application (MAA) for epcoritamab submitted by AbbVie The submissions are support...

Summary Legend Biotech's Carvykti was approved this year for the treatment of fourth and fifth-line-plus multiple myeloma. Carvykti is partnered with J&J, and the launch is off to a strong start despite supply challenges, thanks to the outstanding CARTITUDE-1 trial data. L...